Check for updates

REVIEW

Virotherapy: cancer gene therapy at last? [version 1; peer review: 2 approved]

Alan E. Bilsland¹, Pavlina Spiliopoulou², T. R. Jeffry Evans¹

¹Institute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Glasgow, G61 1QH, UK

²Beatson West of Scotland Cancer Centre, Glasgow, G12 OYN, UK

V1 First published: 30 Aug 2016, 5(F1000 Faculty Rev):2105
<https://doi.org/10.12688/f1000research.8211.1>

Latest published: 30 Aug 2016, 5(F1000 Faculty Rev):2105
<https://doi.org/10.12688/f1000research.8211.1>

Abstract

For decades, effective cancer gene therapy has been a tantalising prospect; for a therapeutic modality potentially able to elicit highly effective and selective responses, definitive efficacy outcomes have often seemed out of reach. However, steady progress in vector development and accumulated experience from previous clinical studies has finally led the field to its first licensed therapy. Following a pivotal phase III trial, Imlygic (talimogene laherparepvec/T-Vec) received US approval as a treatment for cutaneous and subcutaneous melanoma in October 2015, followed several weeks later by its European authorisation. These represent the first approvals for an oncolytic virotherapy. Imlygic is an advanced-generation herpesvirus-based vector optimised for oncolytic and immunomodulatory activities. Many other oncolytic agents currently remain in development, providing hope that current success will be followed by other diverse vectors that may ultimately come to constitute a new class of clinical anti-cancer agents. In this review, we discuss some of the key oncolytic viral agents developed in the adenovirus and herpesvirus classes, and the prospects for further enhancing their efficacy by combining them with novel immunotherapeutic approaches.

Keywords

Cancer gene therapy , oncolytic virus , adenovirus , herpesvirus , cancer immunotherapy , Imlygic

Open Peer Review

Approval Status

	1	2
version 1
30 Aug 2016		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Leonard Seymour**, University of Oxford, Oxford, UK
2. **Hidde J. Haisma**, University of Groningen, Groningen, The Netherlands

Any comments on the article can be found at the end of the article.

Corresponding author: T. R. Jeffry Evans (j.evans@beatson.gla.ac.uk)

Competing interests: The authors declare that they have no competing interests.

Grant information: This work was supported by the Glasgow Experimental Cancer Medicine Centre (funded by Cancer Research UK and the Chief Scientist Office, Scotland).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2016 Bilsland AE *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions.

How to cite this article: Bilsland AE, Spiliopoulou P and Evans TRJ. **Virotherapy: cancer gene therapy at last? [version 1; peer review: 2 approved]** F1000Research 2016, 5(F1000 Faculty Rev):2105 <https://doi.org/10.12688/f1000research.8211.1>

First published: 30 Aug 2016, 5(F1000 Faculty Rev):2105 <https://doi.org/10.12688/f1000research.8211.1>

Introduction

In its broadest sense, the fundamental objective of cancer gene therapy is to transfer therapeutic transgenes specifically to cancer cells while leaving normal cells unharmed. In this paradigm, selectivity can be achieved at any or all of the levels of uptake, transgene expression, or intrinsic tumour sensitivities, and an enormous variety of constructs—coupled with diverse delivery approaches, including viral, bacterial, and chemical vectors—have now been investigated¹. The earliest approaches include gene replacement strategies involving the delivery of a wild-type tumour suppressor gene, which is either lost or deregulated in the target cell. An exemplar of this strategy is restoration of the p53 tumour suppressor that has been widely examined in a variety of preclinical models and clinical studies^{2–6}.

Blocking the expression of activated oncogenes via antisense approaches has also been seen as attractive⁷. However, the absence of positive results in early phase clinical trials has hindered further development of antisense nucleotides, and considerable interest is now focused on optimising oligonucleotide carrier formulations before embarking on further clinical studies⁸. Other strategies for “suicide” or cytotoxic gene therapy include cell lysis to enhance tumour immunogenicity or the introduction of genes that amplify tumour sensitivity to drug or radiation therapies⁹. These areas of gene therapy have been extensively discussed¹⁰. Although measurable clinical activity has been found in a few “first-generation” approaches, such as adenoviral p53 replacement¹¹, highly promising results have recently been obtained utilising replicating viral vectors (oncolytic virotherapy) that help maximise gene transduction in tumour cells. In view of recent progress, we focus on this particular field of gene therapy.

The door for gene therapy in medicine was perhaps opened in November 2012, when the first human gene treatment, alipogene tiparvovec, was granted approval for patients suffering from familial lipoprotein lipase deficiency, a rare autosomal recessive disorder that leads to recurrent pancreatitis¹². Three years later, the approval of a virotherapy for cancer treatment marked a historic moment for cancer gene therapy in the Western world. The precedent has potentially profound importance for cancer therapeutics, since this approval is likely to represent only the first of a new and diverse class of agents. The concept of treating cancer with pathogenic organisms is now over a century old¹³. However, the history of cancer virotherapy has followed cycles of interest and disappointment¹⁴. In the years after the dawn of chemotherapy, as the first anti-cancer agents became available, numerous “oncolytic” viruses were tested for activity¹⁵. Although interest waned after limited clinical successes were achieved, then-recent elucidation of the structure of DNA led even these early investigators to propose modifying viral genomes to rebalance oncolytic versus pathogenic properties¹⁵.

Yet, since the first trial of viral-mediated gene transfer into patient tumours¹⁶, realising the promise of gene therapy to provide an arsenal of exquisitely selective and potent anti-cancer agents has remained elusive until now. On 27 October 2015, Imlygic (talimogene laherparepvec/T-Vec) received full US Food and Drug Administration (FDA) approval for the treatment of melanoma, closely followed by European authorisation on 17 December. These

approvals were a landmark moment, as the first anti-cancer gene therapy agent approved in the West entered into clinical practice.

The remarkable momentum of gene therapy in recent years has been extensively reviewed^{17–20}. However, the most significant clinical success stories until now have remained in fields other than cancer. Many approaches suffer from limited vector penetration in tumours, which is often insufficient to produce substantial efficacy²¹. Thus, conditionally replicating (oncolytic) vectors have been considered by many to be the best candidates for clinical success. Imlygic is an advanced-generation herpes simplex virus type 1 (HSV1) vector optimised for oncolytic activity and armed with the immunostimulatory granulocyte-macrophage colony-stimulating factor (GM-CSF) gene²².

The immunomodulatory aspect of Imlygic activity may point the way to future successes; recently, growing awareness that anti-tumour immune responses mediate the efficacy of oncolytic agents has drawn cancer gene therapies and immunotherapies closer^{23–26}. Indeed, several other oncolytic vectors armed with transgenes to stimulate anti-tumour T-cell responses are currently in development. In this context, another promising approach that has recently demonstrated remarkable clinical activity uses T-lymphocytes engineered with artificial chimeric antigen receptors (T-CARs). These may ultimately prove highly complementary to oncolytic agents.

Oncolytic virotherapy and immunomodulation

Oncolytic virotherapy relies on selective replication of a virus specifically within cancer cells, triggering tumour cell death and vector spread into new cells. A wide range of vector backbones have been investigated, including “naturally oncolytic” organisms such as reovirus^{27–29}. However, most agents comprise attenuated variants of well-characterised viruses. Here we focus on adenovirus and herpesvirus, since these backgrounds have undergone the most extensive vector engineering.

In these, selective replication is commonly achieved by the deletion of viral genes whose products ordinarily suppress cellular sentinels of the cell cycle, or of anti-viral responses. Replication is then facilitated in tumour cells with inactivation of these pathways; if such checkpoints are inactive, the requirement for a viral suppressor is removed. Alternatively, directing tumour-specific expression of the same viral genes using cancer-specific gene promoter elements achieves similarly restricted replication profiles via silencing viral protein expression in normal cells^{9,30}.

Adenovirus replication depends initially on the expression of differentially spliced products of the early phase genes adenovirus early region 1A (E1A) and E1B, which together promote S-phase entry, setting the stage for the viral gene expression programme through multiple interactions with cellular transcription machinery. These include induction of transcription factor E2F by negative regulation of the retinoblastoma protein pRb by E1A and inhibition of checkpoint and apoptosis pathways by E1B^{31,32}.

The earliest notable oncolytic adenovirus is dl1520/Onyx-015³³. An Ad2/Ad5-hybrid lacking the E1B-55K gene, which acts in part through binding and inactivating p53, dl1520 was originally

proposed to replicate selectively in tumour cells lacking p53 function and was originally developed by Onyx Pharmaceuticals (USA)³⁴. However, this mechanism was widely questioned, and subsequent investigations indicated that late functions of E1B-55K, involving the regulation of translation, are rate limiting for dl1520 replication³⁵.

The agent was safely delivered via both intratumoural^{36–40} and intravascular (mainly hepatic arterial) or intraperitoneal routes^{38,41,42}, targeting either primary or secondary malignant hepatic disease. As monotherapy, dl1520 showed modest clinical outcomes, mainly in the form of disease stabilisation; however, when combined with cytotoxics in head and neck tumours and colorectal liver metastases, it conferred re-sensitisation to chemotherapy against which these tumours had previously shown resistance^{39,41,42}. Correlation between p53 mutation status and response to treatment was not shown, however, amplifying uncertainties regarding the virus' mechanism of action. The company halted clinical development in 2003; however, the highly related vector H101 was licensed to Sunway Biotech (China) and was approved for use there in 2005.

Improvements to replicating adenovirus design have since accumulated, including enhanced strategies for restricting replication and modifications to vector tropism. DNX-2401 (DNATRIX Therapeutics [USA]), formerly known as AdΔ24-RGD, is a second-generation Ad5 vector based on an alternative replication-targeting approach. In the original vector, AdΔ24, the viral E1A gene, reintroduced into a first-generation (E1/E3 deleted) backbone, harbours a 24 bp deletion in the pRb binding site in order to restrict efficient replication to cells with a defective pRb/p16/E2F pathway⁴³. Subsequently, tropism of the vector was expanded in AdΔ24-RGD, which contains a short peptide harbouring an integrin-binding RGD motif in the viral receptor-binding protein, known as fibre⁴⁴.

Ad5/Ad2 internalisation involves high-affinity interaction between the terminal “knob” domain of the trimeric fibre and the primary cellular receptor, human coxsackie and adenovirus receptor (hCAR)^{45–47}. Subsequently, interactions between cellular $\alpha\beta 3/\alpha\beta 5$ integrins and RGD sequence motifs in the capsid protein penton mediate endocytosis^{48,49}. Hence, modifications to fibre can target Ad2/Ad5 to alternative receptors. hCAR expression is low in some cancer cells and it can also be sequestered in tight junctions between epithelial cells^{50–52}. RGD modification provides a tropism extension by re-directing high-affinity binding to integrins.

An alternative approach to tropism modification is “pseudotyping”; here, the vector knob domain is wholly replaced by that from a different adenovirus serotype, exhibiting different tropism. For example, Ad3 utilises an alternative receptor to Ad2/Ad5⁵³. Ad5Δ24 vectors expressing the Ad3 knob efficiently infected and replicated in ovarian cancer cells that were resistant to vectors expressing wild-type Ad5 knob⁵⁴. Oncos-102/CGTG-102 (Oncos Therapeutics [Finland]) contains the E1A-Δ24 mutation, is pseudotyped with Ad3 knob, and is also armed by the addition of the GM-CSF gene in the deleted E3 region in order to promote CD8+ T-cell responses against infected cells.

An early trial of CGTG-102 showed that intratumoural or intracavitary delivery in heavily pre-treated patients induced disease responses even when given as a single dose. Furthermore, the vector induced distant anti-tumour immunity⁵⁵. After demonstrating 63% disease stabilisation in 16 patients, treatment was expanded to 115 trial patients. Serial treatment with CGTG-102 resulted in significantly improved survival ($p < 0.0001$) when compared to single dosing and confirmed the safety of repeat dosing²⁴. Efficacy results were assessed radiologically, and the patients deriving most benefit were those with soft tissue sarcoma, ovarian cancer, melanoma, mesothelioma, and breast cancer⁵⁶. Further improvements to the replication targeting of Ad5Δ24 vectors have been made via the third-generation ICOVIR vectors, which combine E1A mutation with tight transcriptional control and translational optimisation⁵⁷.

Most adenoviral vectors are based on well-characterised laboratory strains representing a restricted range of serotypes. ColoAd1 is a chimeric virus, generated through selection by “directed evolution”, whereby a pool of Ad serotypes from groups B-F are passaged through cell lines of breast, colon, prostate, and pancreatic cancer to allow recombination of potent viral serotypes. ColoAd1 “emerged” through a colon cell line (HT-29)-passaging pool, and is a chimera of Ad11 and Ad3 serotypes belonging to adenovirus Group B⁵⁸. When tested on a colon cancer liver-seeding model, it demonstrated increased anti-tumour potency *in vivo* compared to both Ad5 and dl1520.

The group B origin of Colo-Ad1 gives the distinct advantage of an hCAR-independent attachment to cells via principal binding to CD-46 receptor, which is expressed by a variety of tumours such as thyroid, breast, ovarian, endometrial, lung, colorectal, pancreatic, and gastric, and is amplified in higher grade tumours^{59,60}. Proof-of-concept studies are ongoing in bladder/colorectal (NCT02028442) and ovarian (NCT02028117) cancer patients via both systemic and intraperitoneal routes, whilst the combination of ColoAd1 with inhibition of the PD1/PDL1 axis is also planned (NCT02636036).

The herpesviruses present a second major vector background that has undergone significant development. HSV1716 (SEPREHVIR, Virtu Biologics [UK]) is an ICP34.5-deleted first-generation oncolytic HSV1 vector. A 759 bp deletion, which conferred avirulence on intracerebral inoculation, was originally identified in a variant of the HSV1 17+ strain. HSV1716 was developed by re-introduction of this spontaneously arising deletion into the wild-type 17+ background⁶¹. The vector was found to replicate selectively in dividing cells, causing cytotoxicity to tumour cells and regression in xenograft models^{62,63}. Safety was shown following direct intratumoural injection in glioma patients^{64,65} and in the intraoperative setting of injection to tumour-adjacent brain tissue after debulking⁶⁶.

G207 is a second-generation HSV1 vector based on strain F, containing deletions in both loci of ICP34.5 in addition to inactivation of ICP6, thereby disabling the viral ribonucleotide reductase⁶⁷. The vector also showed safety in phase I trials in glioblastoma: initially, a single inoculation dose escalation study was

performed⁶⁸. Subsequently, the vector was tested in an intraoperative setting (pre- and post-resection) and in combination with radiotherapy^{69,70}. A further trial (NCT02457845) is planned to assess the safety of G207 alone or with radiation in paediatric patients, but it is not yet recruiting. NV1020 (R7020), another multiply deleted vector based on strain F, contains a 15 kb deletion of the “joint region”, which includes a single copy of ICP34.5, in addition to the U_L56 gene. This vector is less attenuated than G207.

As noted above, Imlytic is the first oncolytic vector to receive approval in the US and Europe. It is an HSV1 vector optimised in several ways²². The parental strain JS1 was obtained from a new clinical isolate rather than the serially passaged laboratory strains previously utilised in HSV1716 and G207. Unattenuated JS1 demonstrated significantly higher cytotoxic activity than the wild-type 17+ strain in several tumour cell lines. The oncolytic vector was generated by deletion of the ICP34.5 gene in addition to ICP47, which is involved in suppressing antigen presentation⁷¹. Loss of ICP47 therefore promotes an immune response against infected tumour cells, and this aspect is further enhanced through arming with the GM-CSF gene.

The OPTiM trial was the first randomised controlled phase III study of an oncolytic agent to have met its efficacy end-point, and thus enough supporting evidence was provided for its recent approval⁷². Patients with unresected stage III or IV melanoma and with variable lines of previous treatments were randomised to either intralesional treatment of Imlytic, or systemic treatment with GM-CSF. Clinical efficacy was confirmed with 26.4% of patients experiencing an overall response (complete response [CR] or partial response), and in 16.3% of patients this response lasted for more than 6 months.

With a much more favourable toxicity profile than that observed using current immune checkpoint inhibitors, Imlytic also achieved a higher rate of CRs (10% CR rate versus the historic 1–6% rate observed with ipilimumab and pembrolizumab)^{73,74}. Both the

treatment responses and the survival advantage achieved with intralesional Imlytic were statistically significant in patients with earlier stage than M1b/M1c (without visceral metastases or raised lactate dehydrogenase) with a hazard ratio (HR) for overall survival of 0.57 ($p < 0.001$) when compared to treatment with GM-CSF. This effect should not be attributed only to intralesional oncolysis, as 15% of uninjected visceral lesions reduced their size by $\geq 50\%$. Greater benefit, in terms of both response and survival, was also observed in treatment-naïve patients (HR 0.50, $p < 0.001$). The study design minimised treatment discontinuations due to misperceived “pseudo-progressions” allowing patients to be treated for a minimum of 24 weeks if clinically appropriate. Overall, the results confirm the activity of Imlytic in a subset of patients with low-volume injectable melanoma not subjected to multiple lines of treatment. However, it should be noted that systemic GM-CSF is a comparator that lacks a statistically confirmed impact on overall survival⁷⁵. Therefore, further studies are needed to validate the role of Imlytic in the melanoma therapeutic algorithm.

How can the cancer gene therapy field now build on this success? The development of several agents has previously been incentivised via orphan drug designations (Table 1). Most have not yet progressed to pivotal phase III trials, although DNX-2401 may do so in 2016 (<http://www.dnatrix.com/pipeline/>). The approval of Imlytic increases confidence that more approvals could be achieved for vectors that “stay the course”. The wide variety of vector backgrounds being tested is also cause for optimism; this medley of tropisms, lytic cycles, and immunological effects ensures that the agent class is highly diverse.

Imlytic continues development in a number of early phase trials for other solid tumours including pancreatic adenocarcinoma, soft tissue sarcoma, and head and neck squamous cell carcinoma⁷⁶. Furthermore, there may be considerable advantage in combining oncolytic agents with other immunomodulatory strategies. Combination approaches utilising immune checkpoint inhibitors ipilimumab and pembrolizumab are currently being tested,

Table 1. Oncolytic vectors granted US Food and Drug Administration (FDA) orphan drug designation.

Agent	Vector	Company	Disease	Designation year
G207	Herpes simplex virus	Aettis, Inc.	Glioma	2002
NTX-010	Seneca Valley Virus	Neotropix	Neuroendocrine tumours	2008
ONCOS-102	Adenovirus	Oncos Therapeutics	Malignant mesothelioma, ovarian cancer, and glioma	2013–14
DNX-2401	Adenovirus	DNatrix	Glioma	2014
Reolysin	Reovirus	Oncolytics Biotech Inc.	Glioma, gastric cancer, primary peritoneal cancer, fallopian tube cancer, ovarian cancer, and pancreatic cancer	2015

reflecting a view that efficacy gains could be made through further stimulation of anti-tumour immunity beyond those mechanisms inbuilt in the vector. Preliminary results support a possible synergistic effect in treatment-naïve melanoma patients using Imlygic as a priming agent before immune-induction with ipilimumab⁷⁷.

Many mechanisms allow tumours to evade natural immunity that would otherwise recognise and eliminate cancer cells⁷⁸. Cancer immunotherapy uses various approaches to overcome immune tolerance. In particular, the use of T-cells specifically targeted to tumours has shown considerable clinical promise in recent years. Cytotoxic CD8+ T-cells isolated from cancer patients can recognise tumour-associated antigens via the major histocompatibility complex class I antigen presentation pathway⁷⁹. However, *in vivo*, their anti-tumour activities are blunted. Clinical approaches to enhance T-cell responses have included *ex vivo* stimulation of antigen-presenting cells with tumour-derived antigens or mRNA⁸⁰, systemic administration of synthetic peptides capable of binding class I molecules⁸¹, and pharmacological immune-checkpoint inhibitors⁸².

An alternative approach circumventing the requirement for antigen processing and presentation involves T-cells transduced *ex-vivo* with chimeric antigen receptors (T-CARs). The synthetic receptors commonly comprise single-chain antibody fragments serving as the extracellular antigen-recognition domain fused to the CD3ζ transmembrane adaptor signalling domain, with or without additional co-stimulatory domains⁸³. Together, these serve to signal T-cell activation on binding to cell-surface antigens. T-CARs targeted to CD19 have recently demonstrated significant clinical response rates in patients with haematological malignancies, particularly chronic lymphocytic leukaemia^{84–87}. Indeed, sustained responses of several-year duration have been reported in some patients⁸⁸. T-CARs are also being developed against a wide range of solid-tumour antigens⁸⁹.

A particularly interesting avenue for future trials may therefore lie in combining armed immunomodulatory oncolytic agents with T-cell targeting, potentially also alongside immune-checkpoint inhibition. It was recently demonstrated that T-CARs targeted to human epidermal growth factor receptor 2 could act as effective carriers of oncolytic vaccinia or vesicular stomatitis viruses⁹⁰. Neither the oncolytic passengers nor the T-cell vehicles appeared to significantly interfere with each other's activities. However, T-cells are non-permissive for infection by certain vectors, including commonly used adenovirus serotypes, because of low viral receptor expression⁹¹. Nevertheless, alternative approaches could still allow these modalities to be combined: in another study, local delivery to neuroblastoma xenografts of Ad5Δ24 armed with cytokines RANTES and IL15 enhanced infiltration and persistence within the tumour of subsequently delivered T-CARs targeted to the GD2 antigen⁹².

Outlook

There is considerable scope for multi-modal immunogenetic therapies to improve further on emerging successes. However, the approval path for advanced biotherapies is not necessarily straightforward^{93–96}. Various guidelines have been developed to clarify requirements for viral vector programmes^{97,98}. However, to streamline the translation of potentially promising new agents, it is important that researchers adopt a future-focused approach. A recent manifesto calls for a range of practical measures to be embedded in gene therapy programmes. These include using well-defined target-product profiles (as in Pharma), establishing ambitious pre-clinical efficacy cut-offs, planning early for phase I-III clinical studies, and, critically, planning for manufacture and scale-up⁹⁹.

These general principles should be embedded in programmes and may ease clinical development, but we believe that effective trial design is the core of the issue; fundamentally, late-phase trials must achieve their efficacy endpoints. It remains to be seen if oncolytic vectors can be developed that will be effective when administered systemically. Therefore, delivery routes may continue to dictate those tumours that are tractable. Imlygic is delivered by direct intratumoural injection to cutaneous lesions; intraperitoneal delivery is also an attractive localised route in the setting of ovarian cancer¹⁰⁰.

Another key aspect of trial design for gene therapy relates to stratification and pharmacodynamic biomarkers, which will likely prove increasingly critical to the development of gene therapy agents, as for other cancer therapeutics. The absence of suitable stratification markers necessarily leads to a requirement for larger patient groups to identify robust responders. This is clearly undesirable, given that viral vector manufacture and scale-up involve so many variables¹⁰¹. Indeed, infectivity and growth characteristics of oncolytic agents are individually tailored such that process standardisation for any “vector class” is likely to be problematic. These aspects raise difficulties in predicting production requirements for viral gene therapy regimens, issues that will be compounded in moving to larger efficacy trials. For oncolytics, increasing evidence for the role of anti-tumour immunity in mediating efficacy is leading to the investigation of a range of candidate predictive immunological markers^{23,24,26}. On the other hand, given the still-partial mechanistic understanding of some agents, the optimal choice of biomarkers may emerge only during development.

Yet, though the hurdles may be higher, the road to effective gene therapies should be seen in the context of the success rate throughout cancer drug development, even for small molecules¹⁰². Taking an optimistic outlook, if the long process of vector development that led us to this point is viewed analogously to lead optimisation in traditional drug development, then gene therapists do not, at least, need to begin with a new scaffold for each target, unlike medicinal chemists. It is fair to suggest that the wilderness years of gene therapy are in the past and that once the optimal vector

configurations for cancer applications are understood they will be “selectively replicated”. By combining these with innovative new arming approaches and other modalities, the legacy of Dock¹ and others may finally be realised.

Abbreviations

CR, complete response; E1, adenovirus early region 1; GM-CSF, granulocyte-macrophage colony-stimulating factor; hCAR, human coxsackie and adenovirus receptor; HR, hazard ratio; HSV1, herpes simplex virus type 1; T-CARs, chimeric antigen receptor-engineered T-cells.

Competing interests

The authors declare that they have no competing interests.

Grant information

This work was supported by the Glasgow Experimental Cancer Medicine Centre (funded by Cancer Research UK and the Chief Scientist Office, Scotland).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Chira S, Jackson CS, Oprea I, et al.: **Progresses towards safe and efficient gene therapy vectors.** *Oncotarget.* 2015; 6(31): 30675–703.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Clayman GL, el-Naggar AK, Roth JA, et al.: **In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma.** *Cancer Res.* 1995; 55(1): 1–6.
[PubMed Abstract](#)
- Fujiwara T, Grimm EA, Mukhopadhyay T, et al.: **Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene.** *Cancer Res.* 1994; 54(9): 2287–91.
[PubMed Abstract](#)
- Kim J, Hwang ES, Kim JS, et al.: **Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse.** *Cancer Gene Ther.* 1999; 6(2): 172–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pagliari LC, Keyhani A, Liu B, et al.: **Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin.** *Urol Oncol.* 2003; 21(6): 456–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Spitz FR, Nguyen D, Skibber JM, et al.: **In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer.** *Anticancer Res.* 1996; 16(6B): 3415–22.
[PubMed Abstract](#)
- Merdan T, Kopecek J, Kissel T.: **Prospects for cationic polymers in gene and oligonucleotide therapy against cancer.** *Adv Drug Deliv Rev.* 2002; 54(5): 715–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Moreno PM, Pêgo AP.: **Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic.** *Front Chem.* 2014; 2: 87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Keith WN, Bilsland A, Hardie M, et al.: **Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.** *Nat Clin Pract Oncol.* 2004; 1(2): 88–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Das SK, Menezes ME, Bhatia S, et al.: **Gene Therapies for Cancer: Strategies, Challenges and Successes.** *J Cell Physiol.* 2015; 230(2): 259–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Chen GX, Zhang S, He XH, et al.: **Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.** *Onco Targets Ther.* 2014; 7: 1901–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kastelein JJ, Ross CJ, Hayden MR.: **From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world.** *Hum Gene Ther.* 2013; 24(5): 472–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dock G.: **The influence of complicating diseases upon leuk/Emia.*.** *The American Journal of the Medical Sciences.* 1904; 127(4): 563–92.
[Reference Source](#)
- Kelly E, Russell SJ.: **History of oncolytic viruses: genesis to genetic engineering.** *Mol Ther.* 2007; 15(4): 651–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Southam CM.: **Present status of oncolytic virus studies.** *Trans N Y Acad Sci.* 1960; 22(8 Series II): 657–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Oldfield EH, Ram Z, Culver KW, et al.: **Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir.** *Hum Gene Ther.* 1993; 4(1): 39–69.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Crystal RG.: **Adenovirus: the first effective in vivo gene delivery vector.** *Hum Gene Ther.* 2014; 25(1): 3–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Glorioso JC.: **Herpes simplex viral vectors: late bloomers with big potential.** *Hum Gene Ther.* 2014; 25(2): 83–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Miller AD.: **Retroviral vectors: from cancer viruses to therapeutic tools.** *Hum Gene Ther.* 2014; 25(12): 989–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mulligan RC.: **Development of gene transfer technology.** *Hum Gene Ther.* 2014; 25(12): 995–1002.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rots MG, Elferink MG, Gommans WM, et al.: **An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents.** *J Gene Med.* 2006; 8(1): 35–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Liu BL, Robinson M, Han Z, et al.: **ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.** *Gene Ther.* 2003; 10(4): 292–303.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hirvinen M, Heiskanen R, Oksanen M, et al.: **Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment.** *J Transl Med.* 2013; 11: 193.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kanerva A, Nokisalmi P, Diaconu I, et al.: **Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.** *Clin Cancer Res.* 2013; 19(10): 2734–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pesonen S, Diaconu I, Kangasniemi L, et al.: **Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.** *Cancer Res.* 2012; 72(7): 1621–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Taipale K, Liikanen I, Juhila J, et al.: **Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.** *Mol Ther.* 2016; 24(1): 175–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Angelova AL, Geletnek K, Nuesch JP, et al.: **Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.** *Front Bioeng Biotechnol.* 2015; 3: 55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Kemp V, Hoebe RC, van den Wollenberg DJ.: **Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus.** *Viruses.* 2016; 8(1): pii: E4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Al Yaghchi C, Zhang Z, Alusi G, et al.: **Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.** *Immunotherapy.* 2015; 7(12): 1249–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Dorer DE, Nettelbeck DM.: **Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.** *Adv Drug Deliv Rev.* 2009; 61(7–8): 554–71.
[PubMed Abstract](#) | [Publisher Full Text](#)

31. Berk AJ: **Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus.** *Oncogene*. 2005; 24(52): 7673–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Flint J, Shenk T: **Viral transactivating proteins.** *Annu Rev Genet*. 1997; 31: 177–212.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Barker DD, Berk AJ: **Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection.** *Virology*. 1987; 156(1): 107–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Bischoff JR, Kim DH, Williams A, *et al.*: **An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.** *Science*. 1996; 274(5286): 373–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. O'Shea CC, Soria C, Bagus B, *et al.*: **Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy.** *Cancer Cell*. 2005; 8(1): 61–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Galanis E, Okuno SH, Nascimento AG, *et al.*: **Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.** *Gene Ther*. 2005; 12(5): 437–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Habib N, Salama H, Abd El Latif Abu Median A, *et al.*: **Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma.** *Cancer Gene Ther*. 2002; 9(3): 254–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Habib NA, Sarraf CE, Mitry RR, *et al.*: **E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.** *Hum Gene Ther*. 2001; 12(3): 219–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Khuri FR, Nemunaitis J, Ganly I, *et al.*: **a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.** *Nat Med*. 2000; 6(8): 879–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Makower D, Rozenblit A, Kaufman H, *et al.*: **Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.** *Clin Cancer Res*. 2003; 9(2): 693–702.
[PubMed Abstract](#)
41. Reid T, Galanis E, Abbruzzese J, *et al.*: **Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.** *Cancer Res*. 2002; 62(21): 6070–9.
[PubMed Abstract](#)
42. Reid TR, Freeman S, Post L, *et al.*: **Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.** *Cancer Gene Ther*. 2005; 12(8): 673–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Fueyo J, Gomez-Manzano C, Alemany R, *et al.*: **A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.** *Oncogene*. 2000; 19(1): 2–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Suzuki K, Fueyo J, Krasnykh V, *et al.*: **A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.** *Clin Cancer Res*. 2001; 7(1): 120–6.
[PubMed Abstract](#)
45. Bergelson JM, Cunningham JA, Droguett G, *et al.*: **Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5.** *Science*. 1997; 275(5304): 1320–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Kirby I, Davison E, Beavil AJ, *et al.*: **Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR.** *J Virol*. 1999; 73(11): 9508–14.
[PubMed Abstract](#) | [Free Full Text](#)
47. Roelvink PW, Mi Lee G, Einfeld DA, *et al.*: **Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae.** *Science*. 1999; 286(5444): 1568–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Wang K, Huang S, Kapoor-Munshi A, *et al.*: **Adenovirus internalization and infection require dynamin.** *J Virol*. 1998; 72(4): 3455–8.
[PubMed Abstract](#) | [Free Full Text](#)
49. Wickham TJ, Mathias P, Cheres DA, *et al.*: **Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment.** *Cell*. 1993; 73(2): 309–19.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Cohen CJ, Shieh JT, Pickles RJ, *et al.*: **The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.** *Proc Natl Acad Sci U S A*. 2001; 98(26): 15191–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Hamdan S, Verbeke CS, Fox N, *et al.*: **The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gene transfer in pancreatic cancer cells.** *Cancer Gene Ther*. 2011; 18(7): 478–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Strauss R, Sova P, Liu Y, *et al.*: **Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.** *Cancer Res*. 2009; 69(12): 5115–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Wang H, Li ZY, Liu Y, *et al.*: **Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.** *Nat Med*. 2011; 17(1): 96–104.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Kanerva A, Zinn KR, Chaudhuri TR, *et al.*: **Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.** *Mol Ther*. 2003; 8(3): 449–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Cerullo V, Pesonen S, Diaconu I, *et al.*: **Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.** *Cancer Res*. 2010; 70(11): 4297–309.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. **F** Hemminki O, Parviainen S, Juhila J, *et al.*: **Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GM-CSF suggests utility for tumor immunotherapy.** *Oncotarget*. 2015; 6(6): 4467–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
57. Cascallo M, Alonso MM, Rojas JJ, *et al.*: **Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway.** *Mol Ther*. 2007; 15(9): 1607–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Kuhn I, Harden P, Bauzon M, *et al.*: **Directed evolution generates a novel oncolytic virus for the treatment of colon cancer.** *PLoS One*. 2008; 3(6): e2409.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Fishelson Z, Donin N, Zell S, *et al.*: **Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.** *Mol Immunol*. 2003; 40(2–4): 109–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. **F** Segerman A, Atkinson JP, Marttila M, *et al.*: **Adenovirus type 11 uses CD46 as a cellular receptor.** *J Virol*. 2003; 77(17): 9183–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
61. MacLean AR, ul-Fareed M, Robertson L, *et al.*: **Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17: between immediate early gene 1 and the 'a' sequence.** *J Gen Virol*. 1991; 72(Pt 3): 631–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Brown SM, Harland J, MacLean AR, *et al.*: **Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2.** *J Gen Virol*. 1994; 75(Pt 9): 2367–77.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Kesari S, Randazzo BP, Valyi-Nagy T, *et al.*: **Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant.** *Lab Invest*. 1995; 73(5): 636–48.
[PubMed Abstract](#)
64. Papanastassiou V, Rampling R, Fraser M, *et al.*: **The potential for efficacy of the modified (ICP 34.5) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.** *Gene Ther*. 2002; 9(6): 398–406.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Rampling R, Cruickshank G, Papanastassiou V, *et al.*: **Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.** *Gene Ther*. 2000; 7(10): 859–66.
[PubMed Abstract](#)
66. Harrow S, Papanastassiou V, Harland J, *et al.*: **HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.** *Gene Ther*. 2004; 11(22): 1648–58.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Mineta T, Rabkin SD, Yazaki T, *et al.*: **Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.** *Nat Med*. 1995; 1(9): 938–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Markert JM, Medlock MD, Rabkin SD, *et al.*: **Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.** *Gene Ther*. 2000; 7(10): 867–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Markert JM, Liechty PG, Wang W, *et al.*: **Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM.** *Mol Ther*. 2009; 17(1): 199–207.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. **F** Markert JM, Razdan SN, Kuo HC, *et al.*: **A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.** *Mol Ther*. 2014; 22(5): 1048–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
71. Goldsmith K, Chen W, Johnson DC, *et al.*: **Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8⁺ T cell response.** *J Exp Med*. 1998; 187(3): 341–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
72. **F** Andtbacka RH, Kaufman HL, Collichio F, *et al.*: **Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.** *J Clin Oncol*. 2015; 33(25): 2780–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
73. Duad A, Ribas A, Robert C, *et al.*: **Long-term efficacy of pembrolizumab**

- (pembro; MK-3475) in a pooled analysis of 655 patients with advanced melanoma (MEL) enrolled in KEYNOTE-001. *J Clin Oncol*. 2015; 33(suppl): Abstract 9005.
[Reference Source](#)
74. **F** Hodi FS, O'Day SJ, McDermott DF, *et al.*: Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010; 363(8): 711–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 75. Kaufman HL, Ruby CE, Hughes T, *et al.*: Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. *J Immunother Cancer*. 2014; 2: 11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. **F** Greig SL: Talimogene Laherparepvec: First Global Approval. *Drugs*. 2016; 76(1): 147–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 77. **F** Puzanov I, Milhem MM, Minor D, *et al.*: Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. *J Clin Oncol*. 2016; 34(22): 2619–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 78. Vinay DS, Ryan EP, Pawelec G, *et al.*: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Semin Cancer Biol*. 2015; 35(Suppl): S185–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
 79. Kawakami Y, Robbins PF, Rosenberg SA: Human melanoma antigens recognized by T lymphocytes. *Keio J Med*. 1996; 45(2): 100–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 80. Vandenberk L, Belmans J, Van Woensel M, *et al.*: Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. *Front Immunol*. 2015; 6: 663.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 81. Middleton G, Silcocks P, Cox T, *et al.*: Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2014; 15(8): 829–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. **F** Parry RV, Chemnitz JM, Frauwirth KA, *et al.*: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. *Mol Cell Biol*. 2005; 25(21): 9543–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 83. Maus MV, Grupp SA, Porter DL, *et al.*: Antibody-modified T cells: CARs take the front seat for hematologic malignancies. *Blood*. 2014; 123(17): 2625–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 84. Brentjens RJ, Riviere I, Park JH, *et al.*: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood*. 2011; 118(18): 4817–28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 85. **F** Kalos M, Levine BL, Porter DL, *et al.*: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci Transl Med*. 2011; 3(95): 95ra73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 86. Kochenderfer JN, Dudley ME, Feldman SA, *et al.*: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood*. 2012; 119(12): 2709–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 87. **F** Porter DL, Levine BL, Kalos M, *et al.*: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med*. 2011; 365(8): 725–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 88. Mato A, Porter DL: A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. *Blood*. 2015; 126(4): 478–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
 89. **F** Kakarla S, Gottschalk S: CAR T cells for solid tumors: armed and ready to go? *Cancer J*. 2014; 20(2): 151–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 90. **F** VanSeggelen H, Hammill JA, Dvorkin-Gheva A, *et al.*: T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice. *Mol Ther*. 2015; 23(10): 1600–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 91. Schmidt MR, Piekos B, Cabatanga MS, *et al.*: Expression of a human coxsackie/adenovirus receptor transgene permits adenovirus infection of primary lymphocytes. *J Immunol*. 2000; 165(7): 4112–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 92. **F** Nishio N, Diaconu I, Liu H, *et al.*: Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. *Cancer Res*. 2014; 74(18): 5195–205.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 93. Melchiorri D, Pani L, Gasparini P, *et al.*: Regulatory evaluation of Glybera in Europe - two committees, one mission. *Nat Rev Drug Discov*. 2013; 12(9): 719.
[PubMed Abstract](#) | [Publisher Full Text](#)
 94. Narayanan G, Cossu G, Galli MC, *et al.*: Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union. *Hum Gene Ther Clin Dev*. 2014; 25(1): 1–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 95. Watanabe N, Yano K, Tsuyuki K, *et al.*: Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera. *Mol Ther Methods Clin Dev*. 2015; 2: 14066.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 96. Ylä-Herttua S: Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. *Mol Ther*. 2012; 20(10): 1831–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 97. Harmonisation ICo: General principles to address virus and vector shedding ICH Considerations. 2009.
[Reference Source](#)
 98. Harmonisation ICo: Oncolytic viruses ICH Considerations. 2009.
[Reference Source](#)
 99. Cheever TR, Berkley D, Braun S, *et al.*: Perspectives on best practices for gene therapy programs. *Hum Gene Ther*. 2015; 26(3): 127–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 100. Evans TR, Keith WN: Intra-peritoneal administration of genetic therapies: promises and pitfalls. *Minerva Ginecol*. 2004; 56(6): 529–38.
[PubMed Abstract](#)
 101. Merten OW, Schweizer M, Chahal P, *et al.*: Manufacturing of viral vectors for gene therapy: Part I. Upstream processing. *Pharm Bioprocess*. 2014; 2(2): 183–203.
[Publisher Full Text](#)
 102. DiMasi JA, Reichert JM, Feldman L, *et al.*: Clinical approval success rates for investigational cancer drugs. *Clin Pharmacol Ther*. 2013; 94(3): 329–35.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Hidde J. Haisma

Department of Pharmaceutical Gene Modulation, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands

Competing Interests: No competing interests were disclosed.

2. Leonard Seymour

Department of Oncology, University of Oxford, Oxford, UK

Competing Interests: Leonard Seymour chairs the Scientific Advisory Board for PsiOxus, who are developing ColoAd1.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research